Tricida Investor Relations Material
Latest events
Q2 2022
Tricida
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tricida Inc
Access all reports
Tricida Inc. is a pharmaceutical company focused on developing therapies for chronic kidney disease (CKD). The company’s lead investigational drug is designed to treat metabolic acidosis, a common complication in patients with CKD, which can lead to disease progression. Tricida aims to address unmet medical needs in the nephrology space by developing therapies that improve kidney health and patient outcomes. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TCDA
Country
🇺🇸 United States